Monoclonal Antibodies Against Amyloid Beta Peptides

Tech ID: 24265 / UC Case 2014-271-0

Brief Description

Seven monoclonal antibodies that react specifically with amyloid beta peptides can be used as the research tools for Alzheimer’s disease (AD) research.

Full Description

Researchers at UC Irvine’s MIND Institute developed a set of seven hybridoma cell lines that produce monoclonal antibodies specifically against Aβ1-42. Antibodies 124-12, 02-5, 04-3, 55-7, and 56-2 recognize the epitope that resides within the N-terminal amino acids 1-15 of Aβ1-42 peptide. They were tested on western blotting and immunohistochemistry during the development. Antibody 55-7 was also tested as a capture antibody for ELISA. Antibody1313 was made specifically against the Aβx-40 c-terminal CVGGVV peptide. It shows high specificity and reactivity for Aβx-40 and was tested for western blotting, immunohistochemical staining, and ELISA detection antibody purposes. Antibody 1313 also shows significant therapeutically effect in treatment of APP/Tg2576 mouse model of AD. The final monoclonal antibody 2B4 was made reacting to the epitope CVGGVVIA of the c-terminus of Aβx-42 peptide. It has similar research applications as antibody 1313. The above antibodies are used for detection of amyloid beta peptides and valuable for AD research.

Antibodies Information Chart 

Suggested uses

Advantages

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As

  • AN INTEGRAL PART OF
  • Institute for Innovation Logo
  • Institute for Innovation Logo

University of California, Irvine Invention Transfer Group
5141 California Avenue, Suite 200, Irvine,CA 92697-7700
Tel: 949.824.2683 | Fax: 949.824.3880
www.ota.uci.edu | ota@uci.edu

© 2014, The Regents of the University of California
Terms of use | Privacy Notice